Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504916 · ClinicalTrials.gov registry record · Phase 2
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
A Phase 2 study, sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Terminated
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT04504916 is a Phase 2 study that was terminated before completion, run by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 102 participants.
The verdict
NCT04504916, a Phase 2 study, was terminated before completion, sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.
Interventions
- DRUG Zilovertamab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2020-10-07 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504916
The ClinicalTrials.gov registry entry for NCT04504916 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zilovertamab vedotin is the first listed.
NCT04504916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04504916 about?
NCT04504916 is a clinical study titled "A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)". This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, no...
What is the current status of trial NCT04504916?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2020-10-07. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT04504916?
The interventions under investigation include: Zilovertamab vedotin (DRUG).
Who is sponsoring clinical trial NCT04504916?
This trial is sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.